Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck & Co. planning restructuring program

Merck & Co. filed with the U.S. Securities and Exchange Commission that the company plans an extensive restructuring of its manufacturing and supply network.

Read More »

Merck raises full-year 2019 forecasts

Merck & Co. reported higher-than-expected Q1 profit on increased demand for vaccines and the cancer immunotherapy Keytruda, and raised the company’s 2019 earnings and revenue forecasts.

Read More »

Pfizer posts earnings beat, raises 2019 profit forecast

Pfizer beat Wall Street estimates for Q1 profit and slightly raised the company’s 2019 earnings forecast as the largest U.S. drugmaker reined in costs and recorded higher Ibrance and Prevnar sales.

Read More »

Eli Lilly misses estimates for top-selling diabetes drug Trulicity, shares slip

Eli Lilly reported lower-than-expected first-quarter 2019 sales for the company’s top-selling diabetes drug Trulicity, due in part to patient affordability programs.

Read More »

Novartis shares rise after lifting 2019 profit outlook

Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.

Read More »

Fresenius Expands Manufacturing Presence in North Carolina, to Add 445 New Jobs

Fresenius Kabi is investing $100 million in expanding the German company’s manufacturing campus in Wilson County, North Carolina, which will add at least 445 new jobs.

Read More »

W2O Reports 17th Consecutive Year of Double-Digit Revenue Growth

W2O – an innovative, analytics-driven, digital-first marketing and communications firm – reported a 23 percent increase in revenue to $177 million in 2018 from $144 million in 2017.

Read More »

Mylan shares sink due to bleak profit outlook for 2019

Mylan NV shares slid 10 percent after the generic drug maker predicted poor 2019 earnings that led some Wall Street analysts to wonder if the company’s finances would worsen further.

Read More »

New cancer drugs, China give AstraZeneca welcome sales boost

AstraZeneca forecast sales growth for full-year 2019, driven by revenue from cancer medicines and other new treatments.

Read More »

Teva Pharmaceutical sees weaker than expected 2019

Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom